Cinfa Biotech’s Biosimilar is on the Starting Block!

20/11/2015 - 4 minutes

cinfa biosimilar

Recently launched Cinfa Biotech just treated the first subjects in a clinical trial with its biosimilar of Neulasta®!

Cinfa Biotech just announced that the first subjects have been dosed in a clinical trial of B12019, a biosimilar version of Amgen’s Neulasta® (pegfilgrastim) to treat chemotherapy-induced neutropenia. Though chemotherapy is highly effective against cancer, it is also an ordeal for the patient due to its harsh side effects. One example of these side effects is the depletion of neutrophils, leading to a decreased or nonexistent immune response. That is exactly where pegfilgrastim comes in. Cinfa Biotech’s biosimilar, called B12019, is a G-CSF receptor agonist used to stimulate bone marrow to produce more neutrophils and ultimately decrease the incidence of infections in patients undergoing chemotherapy.

Neulasta® is today widely used for different types of cancers and represents a market of about €3.5 bn. The high medical need and the upcoming expiration of Amgen’s patent are pushing forward the development of biosimilars that can offer a more affordable alternative for patients (N.B: biosimilars have an estimated average discount of 15 to 40% compared to the original molecule).

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!